Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers
August 28, 2017 at 16:40 PM EDT
Aug 28 (Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they would collaborate on a clinical trial to evaluate a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers.